



3. SPECIFIC CLINICAL CONSIDERATIONS IN RACIAL AND ETHNIC MINORITY POPULATIONS - HEART FAILURE AND LIPIDS

Important Guidelines, Statements, Reports Suggested Readings and Resources

- Call to Action: Structural Racism as a Fundamental Driver of Health Disparities: A Presidential Advisory from the American Heart Association +
- Circulation journal- focused on disparities +
- American Hospital Association Disparities Toolkit +
- The Groundwater of Racial and Ethnic Disparities Research- A Statement From Circulation: Cardiovascular Quality and Outcomes +
- The Triglyceride Paradox in People of African Descent +
- Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes +
- Cardiovascular disease in racial/ethnic minority populations: illness burden and overview of community-based interventions +
- Disparities in cardiovascular care: Past, present, and solutions +
- Contemporary Reevaluation of Race and Ethnicity With Outcomes in Heart Failure +
- Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients +
- Heart failure drug treatment: the fantastic four +
- Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans +
- Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement +
- Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry +